Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and survival pathway-based molecularly targeted therapy. Th...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2021-12, Vol.14 (12), p.1318
Main Authors: Telang, Nitin T, Nair, Hareesh B, Wong, George Y C
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Cell cycle
Chemotherapy
Chinese herbs
Endocrine therapy
Estrogens
Experiments
Growth factors
growth inhibition
Kinases
Phytochemicals
Population
Proteins
Review
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93
cites cdi_FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93
container_end_page
container_issue 12
container_start_page 1318
container_title Pharmaceuticals (Basel, Switzerland)
container_volume 14
creator Telang, Nitin T
Nair, Hareesh B
Wong, George Y C
description Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and survival pathway-based molecularly targeted therapy. The long-term treatment options are associated with systemic toxicity, spontaneous and/or acquired tumor resistance and the emergence a of drug-resistant stem cell population. These limitations lead to advanced stage metastatic cancer. Current emphasis is on research directions that identify efficacious, naturally occurring agents representing an unmet need for testable therapeutic alternatives for therapy resistant breast cancer. Chinese herbs are widely used in traditional Chinese medicine in women for estrogen related health issues and also for integrative support for cancer treatment. This review discusses published evidence on a TNBC model for growth inhibitory effects of several mechanistically distinct nontoxic Chinese herbs, most of them nutritional in nature, and identifies susceptible pathways and potential molecular targets for their efficacy. Documented anti-proliferative and pro-apoptotic effects of these herbs are associated with downregulation of RB, RAS, PI3K, and AKT signaling, modulation of Bcl-2/BAX protein expressions and increased caspase activity. This review provides a proof of concept for Chinese herbs as testable alternatives for prevention/therapy of TNBC.
doi_str_mv 10.3390/ph14121318
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ed787f058c1e44e293e972f9a606b7b1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ed787f058c1e44e293e972f9a606b7b1</doaj_id><sourcerecordid>2612813354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiMEoqVw4QcgS1wQUsBjO7FzQSpRaVcqcClny3HGG6-y8WInRfvv8bKltJz89eiZV-MpitdAP3De0I-7AQQw4KCeFKcgmCgVE_Lpg_1J8SKlDaWVzOTz4oSLpmokyNPCXMbwax7Iahp85-cQ9-TCOW-N3ZPgSDv4CROSK4xdIn4ihrQ4jstoIvkaehyJC5HcRL8bsfyGazP7WySfI5o0k9ZMFuPL4pkzY8JXd-tZ8ePLxU17VV5_v1y159elFZLNpa0UawQVlXRcKcMcgOVQ1byrasmN7HrLAHtrkFIlAPPBOOgrU_cZ7Rt-VqyO3j6Yjd5FvzVxr4Px-s9FiGtt4uztiBp7qaSjlbKAQiBrODaSucbUtO5kB9n16ejaLd02F8VpjmZ8JH38MvlBr8OtVpIqaA5h3t0JYvi5YJr11iebO2cmDEvSrIYKQDaCZfTtf-gmLHHKrTpQTAHnlcjU-yNlY0gporsPA1QfpkD_m4IMv3kY_x79--38N82OrAU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612813354</pqid></control><display><type>article</type><title>Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Telang, Nitin T ; Nair, Hareesh B ; Wong, George Y C</creator><creatorcontrib>Telang, Nitin T ; Nair, Hareesh B ; Wong, George Y C</creatorcontrib><description>Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and survival pathway-based molecularly targeted therapy. The long-term treatment options are associated with systemic toxicity, spontaneous and/or acquired tumor resistance and the emergence a of drug-resistant stem cell population. These limitations lead to advanced stage metastatic cancer. Current emphasis is on research directions that identify efficacious, naturally occurring agents representing an unmet need for testable therapeutic alternatives for therapy resistant breast cancer. Chinese herbs are widely used in traditional Chinese medicine in women for estrogen related health issues and also for integrative support for cancer treatment. This review discusses published evidence on a TNBC model for growth inhibitory effects of several mechanistically distinct nontoxic Chinese herbs, most of them nutritional in nature, and identifies susceptible pathways and potential molecular targets for their efficacy. Documented anti-proliferative and pro-apoptotic effects of these herbs are associated with downregulation of RB, RAS, PI3K, and AKT signaling, modulation of Bcl-2/BAX protein expressions and increased caspase activity. This review provides a proof of concept for Chinese herbs as testable alternatives for prevention/therapy of TNBC.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph14121318</identifier><identifier>PMID: 34959717</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Breast cancer ; Cancer therapies ; Cell cycle ; Chemotherapy ; Chinese herbs ; Endocrine therapy ; Estrogens ; Experiments ; Growth factors ; growth inhibition ; Kinases ; Phytochemicals ; Population ; Proteins ; Review ; Toxicity</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2021-12, Vol.14 (12), p.1318</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93</citedby><cites>FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93</cites><orcidid>0000-0002-9059-8995</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2612813354/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2612813354?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34959717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Telang, Nitin T</creatorcontrib><creatorcontrib>Nair, Hareesh B</creatorcontrib><creatorcontrib>Wong, George Y C</creatorcontrib><title>Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and survival pathway-based molecularly targeted therapy. The long-term treatment options are associated with systemic toxicity, spontaneous and/or acquired tumor resistance and the emergence a of drug-resistant stem cell population. These limitations lead to advanced stage metastatic cancer. Current emphasis is on research directions that identify efficacious, naturally occurring agents representing an unmet need for testable therapeutic alternatives for therapy resistant breast cancer. Chinese herbs are widely used in traditional Chinese medicine in women for estrogen related health issues and also for integrative support for cancer treatment. This review discusses published evidence on a TNBC model for growth inhibitory effects of several mechanistically distinct nontoxic Chinese herbs, most of them nutritional in nature, and identifies susceptible pathways and potential molecular targets for their efficacy. Documented anti-proliferative and pro-apoptotic effects of these herbs are associated with downregulation of RB, RAS, PI3K, and AKT signaling, modulation of Bcl-2/BAX protein expressions and increased caspase activity. This review provides a proof of concept for Chinese herbs as testable alternatives for prevention/therapy of TNBC.</description><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Chinese herbs</subject><subject>Endocrine therapy</subject><subject>Estrogens</subject><subject>Experiments</subject><subject>Growth factors</subject><subject>growth inhibition</subject><subject>Kinases</subject><subject>Phytochemicals</subject><subject>Population</subject><subject>Proteins</subject><subject>Review</subject><subject>Toxicity</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1v1DAQhiMEoqVw4QcgS1wQUsBjO7FzQSpRaVcqcClny3HGG6-y8WInRfvv8bKltJz89eiZV-MpitdAP3De0I-7AQQw4KCeFKcgmCgVE_Lpg_1J8SKlDaWVzOTz4oSLpmokyNPCXMbwax7Iahp85-cQ9-TCOW-N3ZPgSDv4CROSK4xdIn4ihrQ4jstoIvkaehyJC5HcRL8bsfyGazP7WySfI5o0k9ZMFuPL4pkzY8JXd-tZ8ePLxU17VV5_v1y159elFZLNpa0UawQVlXRcKcMcgOVQ1byrasmN7HrLAHtrkFIlAPPBOOgrU_cZ7Rt-VqyO3j6Yjd5FvzVxr4Px-s9FiGtt4uztiBp7qaSjlbKAQiBrODaSucbUtO5kB9n16ejaLd02F8VpjmZ8JH38MvlBr8OtVpIqaA5h3t0JYvi5YJr11iebO2cmDEvSrIYKQDaCZfTtf-gmLHHKrTpQTAHnlcjU-yNlY0gporsPA1QfpkD_m4IMv3kY_x79--38N82OrAU</recordid><startdate>20211217</startdate><enddate>20211217</enddate><creator>Telang, Nitin T</creator><creator>Nair, Hareesh B</creator><creator>Wong, George Y C</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9059-8995</orcidid></search><sort><creationdate>20211217</creationdate><title>Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer</title><author>Telang, Nitin T ; Nair, Hareesh B ; Wong, George Y C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Chinese herbs</topic><topic>Endocrine therapy</topic><topic>Estrogens</topic><topic>Experiments</topic><topic>Growth factors</topic><topic>growth inhibition</topic><topic>Kinases</topic><topic>Phytochemicals</topic><topic>Population</topic><topic>Proteins</topic><topic>Review</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Telang, Nitin T</creatorcontrib><creatorcontrib>Nair, Hareesh B</creatorcontrib><creatorcontrib>Wong, George Y C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Telang, Nitin T</au><au>Nair, Hareesh B</au><au>Wong, George Y C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2021-12-17</date><risdate>2021</risdate><volume>14</volume><issue>12</issue><spage>1318</spage><pages>1318-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and survival pathway-based molecularly targeted therapy. The long-term treatment options are associated with systemic toxicity, spontaneous and/or acquired tumor resistance and the emergence a of drug-resistant stem cell population. These limitations lead to advanced stage metastatic cancer. Current emphasis is on research directions that identify efficacious, naturally occurring agents representing an unmet need for testable therapeutic alternatives for therapy resistant breast cancer. Chinese herbs are widely used in traditional Chinese medicine in women for estrogen related health issues and also for integrative support for cancer treatment. This review discusses published evidence on a TNBC model for growth inhibitory effects of several mechanistically distinct nontoxic Chinese herbs, most of them nutritional in nature, and identifies susceptible pathways and potential molecular targets for their efficacy. Documented anti-proliferative and pro-apoptotic effects of these herbs are associated with downregulation of RB, RAS, PI3K, and AKT signaling, modulation of Bcl-2/BAX protein expressions and increased caspase activity. This review provides a proof of concept for Chinese herbs as testable alternatives for prevention/therapy of TNBC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34959717</pmid><doi>10.3390/ph14121318</doi><orcidid>https://orcid.org/0000-0002-9059-8995</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals (Basel, Switzerland), 2021-12, Vol.14 (12), p.1318
issn 1424-8247
1424-8247
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ed787f058c1e44e293e972f9a606b7b1
source Publicly Available Content Database; PubMed Central
subjects Breast cancer
Cancer therapies
Cell cycle
Chemotherapy
Chinese herbs
Endocrine therapy
Estrogens
Experiments
Growth factors
growth inhibition
Kinases
Phytochemicals
Population
Proteins
Review
Toxicity
title Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20Inhibitory%20Efficacy%20of%20Chinese%20Herbs%20in%20a%20Cellular%20Model%20for%20Triple-Negative%20Breast%20Cancer&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=Telang,%20Nitin%20T&rft.date=2021-12-17&rft.volume=14&rft.issue=12&rft.spage=1318&rft.pages=1318-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph14121318&rft_dat=%3Cproquest_doaj_%3E2612813354%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-c582940457f388a2f11c31563b5673a7bdc21edcae00841e21eaf1d5a6df11d93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2612813354&rft_id=info:pmid/34959717&rfr_iscdi=true